Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.70
  • Today's Change-0.530 / -2.02%
  • Shares traded2.81k
  • 1 Year change-6.27%
  • Beta0.9790
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8061,0081,409
Total Receivables, Net654955
Total Inventory453219
Prepaid expenses233618
Other current assets, total------
Total current assets9401,1241,501
Property, plant & equipment, net697757
Goodwill, net------
Intangibles, net168.409.66
Long term investments9.226.4316
Note receivable - long term--024
Other long term assets1.211.400.87
Total assets1,0361,2201,610
LIABILITIES
Accounts payable11366126
Accrued expenses715555
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total191911
Total current liabilities203140193
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total373537
Total liabilities240175230
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital2,9752,8932,826
Retained earnings (accumulated deficit)(2196)(1861)(1418)
Treasury stock - common(21)(12)(4.28)
Unrealized gain (loss)------
Other equity, total3826(24)
Total equity7961,0461,380
Total liabilities & shareholders' equity1,0361,2201,610
Total common shares outstanding97296095
Treasury shares - common primary issue4.912.240.04
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.